Cetuximab plus triplet

NIAID Data Ecosystem2026-03-06 收录

结直肠癌肝转移新辅助治疗

肿瘤手术切除率评估

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2518979 数据链接链接失效反馈

官方服务：

资源简介：

Primary objectives: To investigate the rate of patients submitted to surgery for liver metastases after a triplet induction chemotherapy (CPT-11, 5-fluorouracil-leucovorin, oxaliplatin) plus Erbitux in patients with liver metastases from colorectal cancer Primary endpoints: Resection rate of liver metastases

创建时间：

2006-04-15

The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases

结直肠癌肝转移新辅助治疗

抗肿瘤药物疗效评估

This single-arm study will evaluate the resection rate of liver metastases in patients with metastatic colorectal cancer and borderline unresectable liver metastases receiving treatment with bevacizum

NIAID Data Ecosystem90

A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer

结直肠癌肝转移新辅助治疗

靶向联合化疗临床评估

This open-label, single arm, multicenter study evaluated the resection rate in participants with colorectal cancer and previously untreated unresectable liver-only metastases after adding bevacizumab

NIAID Data Ecosystem30

Neoadjuvant chemotherapy with Bevacizumab

结直肠癌肝转移新辅助治疗

靶向药物联合化疗疗效评估

Primary objectives: Assessment of the efficacy of the combination of Bevacizumab with irinotecan- based chemotherapy (FOLFIRI) or oral capecitabine (XELIRI) in terms of resectability of the primary no

NIAID Data Ecosystem10

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

结直肠癌肝转移新辅助治疗

肿瘤转化医学研究

FC-6 is a Phase II, multi-center clinical trial for patients with unresectable, wild-type K-RAS, colorectal cancer with metastases confined to the liver. Liver metastases must be determined by FC-6 cr

NIAID Data Ecosystem30

Phase II study of resection of primary colorectal caner and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + Bevacizumab(Bmab) therapy and adjuvant S-1 chemotherapy

结直肠癌肝转移新辅助治疗

II期临床试验

Interventions: S-1 is administered orally at 80mg/m2/day for 14 consecuitive days followed by a 7 day rest. L-OHP is given intravenously on days 1, at a dose of 130mg/m2/day.Bevacizumab is given intra

NIAID Data Ecosystem20

Cetuximab plus triplet

资源简介：

相关数据集